Albert Bourla
Showing 1–4 of 4 transcripts.
- Lex Fridman1h 8m
Albert Bourla: Pfizer CEO | Lex Fridman Podcast #249
Host Alex Friedman engages Pfizer CEO Albert Bourla to dismantle pandemic-era polarization by detailing the company's $2.3 billion strategic gamble and the rigorous, transparent regulatory processes that secured global approval for its vaccines. Bourla clarifies the scientific realities behind the record-breaking development timelines, addresses controversies regarding data transparency and workforce mandates, and outlines Pfizer's capacity to rapidly adapt manufacturing for future variants or new antiviral therapies like Paxlovid. Through this dialogue, the discussion moves beyond conspiracy theories to focus on the intersection of high-stakes financial investment, strict safety protocols, and the human imperative to bridge trust gaps through empathetic science communication.
- Milken Institute1h 0m
In Search for a Cure: Are We Nearing a Treatment for COVID-19?
Dr Anthony Fauci, Albert Bourla, Esther Krofah, Meg Tirrell
Dr. Anthony Fauci and Pfizer executives outlined the current U.S. pandemic crisis, characterized by rising infections among young demographics and projected second-wave risks in the fall due to premature reopening and asymptomatic spread. While addressing safety protocols like sample pooling for testing and the inclusion of vulnerable populations in trials, Pfizer anticipates initiating Phase 3 trials in July with a potential vaccine rollout by late 2020 or early 2021. Simultaneously, clinical guidelines have been updated to include dexamethasone for severe cases, though experts emphasize that continued public health measures remain essential until herd immunity is achieved.
- Milken Institute1h 2m
In Search for a Cure: Are We Nearing a Treatment for COVID-19?
Esther Kofa, Meg Terrell, Dr. Tony Fauci, Albert Bourla
The Milken Institute Summer Series concluded by analyzing the U.S. resurgence of COVID-19 infections and the global development of nearly 250 treatment compounds, featuring critical insights from Dr. Anthony Fauci and Pfizer CEO Dr. Albert Bourla. Dr. Fauci warned of severe fall surges driven by behavioral shifts while outlining a vaccine timeline with Phase III trials expected to begin in July, whereas Dr. Bourla detailed Pfizer's autonomous mRNA strategy aiming for safety and efficacy data by September. As the organization prepares its 23rd Global Conference for a likely online format in October, these discussions underscored the urgent need for robust public health protocols alongside rapid medical solutions.
- Milken Institute58 min
London Summit 2015 - Tech Rx: Harnessing Big Data to Cure Disease
Margaret Anderson, Mary Baker, Albert Bourla, Gianrico Farrugia, Nicole Mather, Nicola Perrin
Hosted by Margaret Anderson of Faster Cures, this session united stakeholders from the European Brain Council, Mayo Clinic, Pfizer, and the UK government to discuss leveraging big data for accelerating disease cures. Key speakers highlighted critical progress in utilizing real-world data for clinical decisions while underscoring persistent barriers regarding data quality, privacy regulations, and public trust. The collective outcome emphasized a strategic shift toward unified global data infrastructure and patient-centered outcomes to transform biomedical research from hypothesis generation into actionable, equitable therapies.